99 related articles for article (PubMed ID: 1394186)
1. DNA strand breaks and DNA cross-links in peripheral mononuclear blood cells of ovarian cancer patients during chemotherapy with cyclophosphamide/carboplatin.
Hengstler JG; Fuchs J; Oesch F
Cancer Res; 1992 Oct; 52(20):5622-6. PubMed ID: 1394186
[TBL] [Abstract][Full Text] [Related]
2. Paclitaxel, cisplatin, and cyclophosphamide in human ovarian cancer: molecular rationale and early clinical results.
Reed E; Kohn EC; Sarosy G; Dabholkar M; Davis P; Jacob J; Maher M
Semin Oncol; 1995 Jun; 22(3 Suppl 6):90-6. PubMed ID: 7541159
[TBL] [Abstract][Full Text] [Related]
3. Correlation of therapeutic outcome in non-small cell lung cancer and DNA damage assayed by polymerase chain reaction in leukocytes damaged in vitro.
Oshita F; Yamamoto N; Fukuda M; Ohe Y; Tamura T; Eguchi K; Shinkai T; Saijo N
Cancer Res; 1995 Jun; 55(11):2334-7. PubMed ID: 7757984
[TBL] [Abstract][Full Text] [Related]
4. ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date.
Harper P
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-23-S15-25. PubMed ID: 9346217
[TBL] [Abstract][Full Text] [Related]
5. New platinum, titanium, and ruthenium complexes with different patterns of DNA damage in rat ovarian tumor cells.
Frühauf S; Zeller WJ
Cancer Res; 1991 Jun; 51(11):2943-8. PubMed ID: 2032232
[TBL] [Abstract][Full Text] [Related]
6. Dose escalation of paclitaxel with high-dose carboplatin using peripheral blood progenitor cell support in patients with advanced ovarian cancer.
Fennelly DW; Aghajanian C; Shapiro F; O'Flaherty C; O'Connor K; Curtin JP; Crown JP; Hoskins WJ; Spriggs DR
Semin Oncol; 1997 Feb; 24(1 Suppl 2):S2-26-S2-30. PubMed ID: 9045332
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.
Thigpen T; Vance R; Puneky L; Khansur T
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816
[TBL] [Abstract][Full Text] [Related]
8. A Gynecologic Oncology Group study of platinum-DNA adducts and excision repair cross-complementation group 1 expression in optimal, stage III epithelial ovarian cancer treated with platinum-taxane chemotherapy.
Darcy KM; Tian C; Reed E
Cancer Res; 2007 May; 67(9):4474-81. PubMed ID: 17483363
[TBL] [Abstract][Full Text] [Related]
9. DNA damage in peripheral blood lymphocytes in patients during combined chemotherapy for breast cancer.
Sánchez-Suárez P; Ostrosky-Wegman P; Gallegos-Hernández F; Peñarroja-Flores R; Toledo-García J; Bravo JL; Del Castillo ER; Benítez-Bribiesca L
Mutat Res; 2008 Apr; 640(1-2):8-15. PubMed ID: 18207203
[TBL] [Abstract][Full Text] [Related]
10. Effect of carboplatin based combination chemotherapy on ovarian cancer.
Feng Y; Zhang X; Sun H
Chin Med J (Engl); 1996 May; 109(5):349-52. PubMed ID: 9208489
[TBL] [Abstract][Full Text] [Related]
11. In vivo DNA cross-linking by cyclophosphamide: comparison of human chronic lymphatic leukemia cells with mouse L1210 leukemia and normal bone marrow cells.
DeNeve W; Valeriote F; Edelstein M; Everett C; Bischoff M
Cancer Res; 1989 Jul; 49(13):3452-6. PubMed ID: 2731167
[TBL] [Abstract][Full Text] [Related]
12. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
13. Quantification of free plasma DNA before and after chemotherapy in patients with advanced epithelial ovarian cancer.
Capizzi E; Gabusi E; Grigioni AD; De Iaco P; Rosati M; Zamagni C; Fiorentino M
Diagn Mol Pathol; 2008 Mar; 17(1):34-8. PubMed ID: 18303408
[TBL] [Abstract][Full Text] [Related]
14. Paradoxical increase in DNA cross-linking in a human ovarian carcinoma cell line resistant to cyanomorpholino doxorubicin.
Lau DH; Ross KL; Sikic BI
Cancer Res; 1990 Jul; 50(13):4056-60. PubMed ID: 2162251
[TBL] [Abstract][Full Text] [Related]
15. Cycles of dose-intensive chemotherapy with peripheral stem cell support in persistent or recurrent platinum-sensitive ovarian cancer.
Morgan MA; Stadtmauer EA; Luger SM; Porter DL; Mangan PA; O'Neil P; Kamelle S; Benjamin I; Mick R; King SA; Rubin SC
Gynecol Oncol; 1997 Dec; 67(3):272-6. PubMed ID: 9441774
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous dose escalation and schedule intensification of carboplatin-based chemotherapy using peripheral blood progenitor cells and filgrastim: a phase I trial.
Fennelly D; Wasserheit C; Schneider J; Hakes T; Reich L; Curtin J; Yao TJ; Markman M; Norton L; Crown J
Cancer Res; 1994 Dec; 54(23):6137-42. PubMed ID: 7525055
[TBL] [Abstract][Full Text] [Related]
17. Inductively coupled plasma mass spectroscopy quantitation of platinum-DNA adducts in peripheral blood leukocytes of patients receiving cisplatin- or carboplatin-based chemotherapy.
Bonetti A; Apostoli P; Zaninelli M; Pavanel F; Colombatti M; Cetto GL; Franceschi T; Sperotto L; Leone R
Clin Cancer Res; 1996 Nov; 2(11):1829-35. PubMed ID: 9816137
[TBL] [Abstract][Full Text] [Related]
18. Collection of peripheral blood stem cells following administration of paclitaxel, cyclophosphamide, and filgrastim in patients with breast and ovarian cancer.
Weaver CH; Schwartzberg LS; Birch R; Greco FA; Hainsworth J; Drapkin R; Campos L; Grapski R; Schwerkoske J; Lautersztain J; Hazelton B; Schnell F; Babcock W; Buckner CD
Biol Blood Marrow Transplant; 1997 Jun; 3(2):83-90. PubMed ID: 9267668
[TBL] [Abstract][Full Text] [Related]
19. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
Wadler S; Yeap B; Vogl S; Carbone P
Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
[TBL] [Abstract][Full Text] [Related]
20. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]